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Case description
A 49-year-old man presented to the cognitive and memory 
disorder outpatient clinic for work up of rapid cognitive 
decline. Patient’s family reported that his symptoms started 
with confusion, memory, and language impairment (naming 
errors and comprehension difficulties) 5–6 months prior to 
presentation. Soon after developing cognitive impairment, 
he developed gait abnormalities and action tremor. The 
symptoms were worsening. His decision-making became 
impaired and he had to retire from work 1 month after the 
onset of his symptoms. His medical history was remarkable 
for childhood dyslexia and lymphoma treated with chemo-
therapy more than a decade ago. There was no family history 
of neurological disorders. He was a former smoker with no 
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history of alcohol or drug use. There was no recent travel 
history. The patient has never had any neurosurgical or oph-
thalmological procedures done.
On the initial evaluation, the patient was alert and awake 
but only oriented to person. He appeared emotionally labile 
and demonstrated frequent verbal and motor perseverations, 
echolalia, and echopraxia. Processing time was prolonged. 
Working memory and visuospatial functions were impaired 
and he had difficulty with object naming and recognition. 
General neurologic examination did not demonstrate myo-
clonus or other types of adventitious movements. His muscle 
tone was normal and gait evaluation demonstrated mild 
ataxia. Deep tendon reflexes were brisk throughout.
The patient had two magnetic resonance imaging (MRIs) of 
the brain performed: the first, 1 month into the disease and the 
second, 5 months later. Both brain scans demonstrated restricted 
diffusion in a gyral pattern along the cortical gray matter in 
bilateral parietal and occipital lobes, with lesser involvement of 
prefrontal cortical gray matter. Primary motor and sensory cor-
tices were spared. There were mild signal changes in the corre-
sponding regions on fluid attenuation inversion recovery 
(FLAIR) sequences. There were no signal changes in subcorti-
cal structures and no gadolinium enhancement present. 
Fluorodeoxyglucose-positron emission tomography (FDG-
PET) scan of the brain showed diminished metabolism, pre-
dominantly in the posterior brain regions.
Cerebrospinal fluid analysis was performed twice. 
Concentrations of amyloid-β (Aβ42), total-tau (t-tau), phos-
pho-tau181 (p-tau), and Aβ42-Tau Index (ATI) were meas-
ured by commercial assay (Athena) on the first cerebrospinal 
fluid (CSF) specimen. It was negative for protein 14-3-3 
(Aβ42—498.95 pg/ml, t-tau—654.45 pg/ml, p-tau—43.4 
pg/ml, ATI—0.49).
The second CSF analysis performed 4 months later dem-
onstrated t-tau protein of 1179 pg/mL (>1150: 76% probabil-
ity of prion disease), negative for 14-3-3 protein, and 
negative real-time quaking-induced conversion (RT-QuIC). 
Neuron-specific enolase was within normal limit (1.6 μg/L), 
with reference range of 1.0–7.0).
A routine 45-min electroencephalography (EEG) was 
obtained. It demonstrated diffuse background slowing at 2–5 
Hz without epileptiform features. As part of a comprehen-
sive evaluation of the patient, he was admitted to the inpa-
tient neurology service and continuous video EEG monitoring 
was started. The long-term monitoring went on for almost 38 
h and demonstrated generalized medium-to-high amplitude 
slowing, more prominent in bilateral frontal regions at 2–6 
Hz frequencies. At times, it demonstrated rhythmic 1–2 Hz 
discharges. Although a normal posterior dominant rhythm 
with a frequency of 8–9 Hz in the most alert state with atten-
uation with eye opening was identified, the study was con-
sidered abnormal due to generalized, intermittent rhythmic 
slowing and absence of normal sleep structures. The routine 
and long-term EEGs were performed approximately 6 
months after emerging of the initial symptoms (Figure 1).
The patient rapidly deteriorated and developed severe 
aphasia, apraxia, agnosia, and abulia. He died 8 months after 
developing the initial clinical symptoms.
The patient underwent an autopsy. The brain tissue was 
sent for special analysis for confirmation of the diagnosis. 
Western blot, histopathological, and immunohistochemical 
examination of the autopsied tissue demonstrated the pres-
ence of abnormal protease-resistant prion protein PrPSc (PrP 
27-30) confirming the diagnosis of MM2 subtype of spo-
radic Creutzfeldt–Jakob disease (sCJD) according to the old 
and current criteria for classification of sporadic prion dis-
ease.1,2 The prion protein (PRNP) gene sequencing analysis 
did not demonstrate pathogenic mutation at the coding region 
of the PRNP gene, therefore a familial prion disease was 
ruled out based on the current criteria.
Discussion
Prion diseases or transmissible spongiform encephalopathies 
are a group of fatal neurodegenerative disorders caused by 
the conversion of the normal prion protein (PrPC) with a pri-
marily α-helical structure into an abnormal form of the pro-
tein called the scrapie prion protein (PrPSc).3,4 Human prion 
diseases can occur as spontaneous (sporadic), genetic (famil-
ial), and acquired (infectious/transmitted). The 80%–95% of 
cases are sCJDs, 10%–15% are genetic (often familial), and 
less than 1% are acquired.5
Sporadic forms of prion disease include sCJD, fatal 
insomnia, and the recently identified variably protease-sen-
sitive prionopathy.6
More than 90% of all sporadic forms are Creutzfeldt–
Jakob disease (CJD). Based on the predominant clinical 
signs, histological and molecular findings, sCJD is com-
monly categorized into five subtypes with three affecting 
prominently cognitive functions and the other two—cerebel-
lar motor activities.5
The codon 129 polymorphism and the existence of one of 
the two types of protease-resistant PrP are the major determi-
nants of phenotypic heterogeneity in sCJD. On the basis of 
these characteristics, six molecular subtypes of the sCJD can 
be identified: MM1, MV1 (both are also called Typical), 
VV1 (Early onset), MM2 (Long duration), MV2 (Kuru 
plaques), and VV2 (Ataxic).7 Each genotype corresponds to 
a different clinical and neuropathological phenotype. The 
MM2 genotype is characterized clinically by progressive 
dementia with ataxia and typical EEG changes being less 
common.8
The sCJD MM2 subtype (combination of methionine 
homozygosity and PrPsc type 2) has a thalamic form 
(MM2T) and a cortical form (MM2C). Pathologically, large 
confluent vacuoles and perivacuolar labeling for PrP in all 
cortical layers characterizes the MM2C subtype.2
MM2T and MM2C subtypes are rare (only 1% of sCJD 
cases each). A phenotype with combined features of both 
subtypes (MM2T + C) has been rarely described as well.9
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MM2C subtype is a late-onset, slowly progressive form 
frequently associated with cortical hyperintense signals on 
diffusion-weighted magnetic resonance imaging (DW-MRI) 
sequences and elevated CSF levels of 14-3-3 protein.
Cortical hyperintense signals present on diffusion-
weighted sequences of brain MRI are useful for the diagnosis 
of the cortical form. Whereas, in the thalamic form, thalamic 
hypoperfusion, and hypometabolism can be demonstrated 
using brain single photon emission computed tomography 
(SPECT) and FDG-PET scans, respectively.
Hamaguchi et al.10 proposed a diagnostic criteria for 
MM2C sCJD—(1) progressive dementia, (2) cortical hyper-
intense signal changes on diffusion-weighted imaging 
(DWI), and (3) increased CSF 14-3-3 protein level—and 
exclusion of other types of cognitive disorders. Other neu-
ropsychiatric abnormalities or periodic sharp wave com-
plexes seen on EEG are not necessarily required.10
EEG in CJD
Periodic sharp wave complexes (PSWCs) are symmetrical 
generalized triphasic, biphasic, or mixed complexes occur-
ring approximately every second on the EEG. This periodic 
EEG pattern is characteristic and, in the right clinical setting, 
consistent with CJD but is not pathognomonic. Detection of 
PSWCs during EEG recording is associated with a sensitiv-
ity of 67% and specificity of 86% for detection of CJD.11
EEG changes evolve during the disease.12 Lateralized 
PSWCs have been described early in the disease course. 
However, nonspecific diffuse slowing background or other 
nonspecific signs of cerebral dysfunction are most com-
monly detected early EEG abnormalities.13 Lateralized 
PSWCs sometimes progress to more symmetrical and gener-
alized complexes. The characteristic PSWCs are commonly 
seen during the second phase of the disease, usually about 3 
months after the initial presentation. With time, the back-
ground amplitude becomes attenuated and the frequency of 
PSWCs starts declining.
Different studies have reported that majority CJD patients 
would develop PSWCs at some point during the disease; 
however, this finding is neither 100% specific nor sensitive.
EEG findings are being studied in patient groups classi-
fied according to PRNP gene polymorphism. In a study by 
Iwasaki et al. among 18 MM1-type cases, PSWCs were 
observed in 17 (94.4%) cases. Meanwhile, in the two tha-
lamic MM2-type cases, PSWCs were not observed. Parchi 
Figure 1. Long-term EEG monitoring demonstrated intermittent rhythmic generalized slowing (1–2 Hz).
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et al.1 did not find PSWCs in six cortical and six thalamic 
MM2 CJD patients.
In a study by Jansen et al., all five MM1 patients showed 
typical EEG findings, but the only patient with MM2 sub-
type was found to have atypical EEG findings, which were 
nonspecific in nature. PSWCs are reported to be detected in 
42% of MM2 patients. Based on the proposed criteria, detec-
tion of PSWCs in routine EEG helps with diagnosing the 
patient with probable CJD (Figure 2).2,14
Conclusion
However, there is no data available to date to demonstrate 
whether increasing the duration of EEG recording could 
improve the sensitivity of detection of abnormalities asso-
ciated with sCJD. It is also not known whether topograph-
ical localization of PSWCs correlates with the regions 
of signal abnormalities detected on DWI imaging of the 
brain.
In the absence of other findings, the use of long-term 
EEG could be implemented to increase the sensitivity of 
EEG in diagnosing sCJD.
The lack of the PSWCs on EEG in some cases could be 
due to insufficient time of recording. Increasing the duration 
of EEG monitoring can increase the diagnostic sensitivity by 
capturing episodes of PSWCs if the clinical picture and 
supporting data are otherwise equivocal.
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